Critical to the mechano-regulation of mesenchymal stem cells (MSC), Linker of the Nucleoskeleton and Cytoskeleton (LINC) complex transduces cytoskeletal forces to the nuclei. The LINC complex contains outer nuclear membrane Nesprin proteins that associate with the cytoskeleton and their inner nuclear membrane couplers, SUN proteins. Here we tested the hypothesis that severing of the LINC complex-mediated cytoskeletal connections may have different effects on chromatin organization and MSC differentiation than those due to ablation of SUN proteins.
View Article and Find Full Text PDFIntroduction And Objectives: There are limited data examining racial disparities in PSC-related clinical features and events. We aimed to leverage a new PSC ICD-10 code to characterize racial differences in a nationwide contemporary cohort of patients with PSC.
Patients And Methods: We used de-identified clinical/administrative data from the Vizient® Clinical Data Base to identify outpatient and inpatient adult patients with PSC using a PSC-specific ICD-10-CM code (K83.
BackgroundStudies show satisfaction with telemedicine, but there is limited data regarding changes in provider practices and clinical outcomes. We sought to evaluate the impact of telehealth on patient-provider communications between visits and clinical outcomes in patients with cirrhosis during the COVID-19 pandemic.MethodsSingle-center retrospective study of cirrhotic patients seen outpatient in 2019 and 2020 was conducted.
View Article and Find Full Text PDFJ Child Adolesc Psychopharmacol
February 2025
Viloxazine extended-release (VLX-ER) is effective as monotherapy for attention-deficit/hyperactivity disorder (ADHD), and is often tried as an add-on treatment when psychostimulant therapy fails to provide an adequate treatment response. This phase 4, open-label study evaluated safety, tolerability, and efficacy of VLX-ER with optimized psychostimulants in pediatric participants with ADHD. Morning versus evening VLX-ER use was also evaluated.
View Article and Find Full Text PDFWe performed an update (last search: 24 July 2023) of a systematic review on relative efficacy/effectiveness (rVE) and safety of newer/enhanced seasonal influenza vaccines in comparison with standard influenza vaccine or in head-to-head comparison. Eligible studies investigated adults aged ≥ 18 years, analysed the MF59-adjuvanted or high-dose or cell-based or recombinant or mRNA-based influenza vaccine and reported rVE or safety in randomised controlled trials (RCT) or non-randomised studies of interventions (NRSI). Of 1561 new entries identified, 17 studies were included.
View Article and Find Full Text PDF